New clinical trials with vitamin D and analogs in renal disease.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 21832981.
- Also identified by DOI 10.1038/ki.2011.260 and PMC identifier 4450646.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Two new clinical trials highlight refinements in the use of vitamin D and its analogs in the treatment of secondary hyperparathyroidism in end-stage renal disease (ESRD), and the treatment of proteinuria in diabetics. In patients with ESRD, alfacalcidol is as effective as paricalcitol in suppressing parathyroid hormone; the occurrence of hypercalcemia and hyperphosphatemia is infrequent and similar with the two analogs. Oral cholecalciferol reduces albuminuria and urinary transforming growth factor-β1 in patients with type 2 diabetes mellitus and proteinuria.
Medical subject headings
- Albuminuria
- Cholecalciferol
- Diabetes Mellitus, Type 2
- Diabetic Nephropathies
- Ergocalciferols
- Hydroxycholecalciferols
- Hyperparathyroidism, Secondary
- Renal Dialysis
- Renin-Angiotensin System
- Transforming Growth Factor beta1